61 results
8-K
EX-99.1
FGEN
FibroGen Inc
20 Aug 21
Other Events
12:00am
in the European Union,” said Steven Benner, M.D., M.H.S., President of Development, Astellas. “Today’s approval provides patients, regardless … to adult patients with anemia of CKD in countries across the European Union.”
CKD impacts one in 10 people globally, of whom one in five are affected
8-K
EX-99.1
FGEN
FibroGen Inc
9 May 22
FibroGen Reports First Quarter 2022 Financial Results
4:09pm
is approved in European Union (EU) member states, including the European Economic Area (EEA) countries, as well as in Japan, China, Chile, South Korea
8-K
EX-99.1
FGEN
FibroGen Inc
28 Feb 22
FibroGen Reports Fourth Quarter and Full Year 2021 Financial Results
4:06pm
is approved in European Union (EU) member states, including the European Economic Area (EEA) countries, as well as in Japan, China, Chile, and South Korea
8-K
EX-99.1
FGEN
FibroGen Inc
9 Nov 21
FibroGen Reports Third Quarter 2021 Financial Results
4:06pm
with myelodysplastic syndromes (MDS), and for chemotherapy-induced anemia (CIA).
Roxadustat is approved in European Union (EU) member states, including
8-K
EX-99.1
FGEN
FibroGen Inc
25 Jun 21
Astellas Receives Positive CHMP Opinion for EVRENZOTM (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease
5:26pm
be reviewed by the EC, which has the authority to approve medicines for European Union member states, as well as Iceland, Norway, Liechtenstein and Northern
S-1
EX-10.8
g7tyqv 1lwjx5t6
1 Oct 14
IPO registration
12:00am